Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc. - Common Stock
(NQ:
APVO
)
8.399
-0.411 (-4.67%)
Streaming Delayed Price
Updated: 10:45 AM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptevo Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Which stocks are gapping on Friday?
↗
April 04, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via
Chartmill
What's going on in today's session
↗
April 03, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
April 03, 2025
Via
AB Newswire
Topics
Intellectual Property
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
February 15, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 14, 2025
Via
ACCESS Newswire
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
December 12, 2024
Via
ACCESSWIRE
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
April 03, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via
Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
April 03, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
11 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 03, 2025
Via
Benzinga
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High
↗
April 03, 2025
The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.
Via
Stocktwits
Topics
Government
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
December 04, 2024
Via
ACCESSWIRE
What's Going On With Aptevo Therapeutics Shares Friday?
↗
November 29, 2024
Aptevo stock is trading lower after the company announced a 1-for-37 reverse stock split.
Via
Benzinga
These stocks that are showing activity before the opening bell on Thursday.
↗
April 03, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 03, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 03, 2025
Via
Benzinga
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
April 03, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
↗
April 02, 2025
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
April 02, 2025
Via
Benzinga
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
↗
March 20, 2025
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment nearing completion.
Via
Benzinga
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
March 20, 2025
Via
ACCESS Newswire
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
March 18, 2025
Via
ACCESS Newswire
Aptevo to Participate in March Conferences
March 06, 2025
Via
ACCESS Newswire
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
January 15, 2025
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 12, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
November 29, 2024
Via
ACCESSWIRE
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
November 26, 2024
Via
ACCESSWIRE
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
November 22, 2024
Via
ACCESSWIRE
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
November 20, 2024
Via
ACCESSWIRE
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
November 11, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
